BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 35393416)

  • 1. CHMP2A regulates tumor sensitivity to natural killer cell-mediated cytotoxicity.
    Bernareggi D; Xie Q; Prager BC; Yun J; Cruz LS; Pham TV; Kim W; Lee X; Coffey M; Zalfa C; Azmoon P; Zhu H; Tamayo P; Rich JN; Kaufman DS
    Nat Commun; 2022 Apr; 13(1):1899. PubMed ID: 35393416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CHMP2A regulates broad immune cell-mediated antitumor activity in an immunocompetent in vivo head and neck squamous cell carcinoma model.
    Yun J; Saddawi-Konefka R; Goldenson B; Al-Msari R; Bernareggi D; Thangaraj JL; Tang S; Patel SH; Luna SM; Gutkind JS; Kaufman D
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38702144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDX2 enhances natural killer cell-mediated immunotherapy against head and neck squamous cell carcinoma through up-regulating CXCL14.
    Wang H; Nan S; Wang Y; Xu C
    J Cell Mol Med; 2021 May; 25(10):4596-4607. PubMed ID: 33733587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition.
    Crist M; Yaniv B; Palackdharry S; Lehn MA; Medvedovic M; Stone T; Gulati S; Karivedu V; Borchers M; Fuhrman B; Crago A; Curry J; Martinez-Outschoorn U; Takiar V; Wise-Draper TM
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36328378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Down-regulation of HLA-B-associated transcript 3 impairs the tumoricidal effect of natural killer cells through promoting the T cell immunoglobulin and mucin domain-containing-3 signaling in a mouse head and neck squamous cell carcinoma model.
    Yang J; Xiang J; Zhu M; Zhao Y; Zhou L; Hu B; Wang C
    Immunobiology; 2022 Jan; 227(1):152127. PubMed ID: 34968777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies.
    Friedman J; Morisada M; Sun L; Moore EC; Padget M; Hodge JW; Schlom J; Gameiro SR; Allen CT
    J Immunother Cancer; 2018 Jun; 6(1):59. PubMed ID: 29925431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of natural killer cell therapy combined with chemoradiotherapy in murine models of head and neck squamous cell carcinoma.
    Jung EK; Chu TH; Kim SA; Vo MC; Nguyen VT; Lee KH; Jung SH; Yoon M; Cho D; Lee JJ; Yoon TM
    Cytotherapy; 2024 Mar; 26(3):242-251. PubMed ID: 38142382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bitter Melon Enhances Natural Killer-Mediated Toxicity against Head and Neck Cancer Cells.
    Bhattacharya S; Muhammad N; Steele R; Kornbluth J; Ray RB
    Cancer Prev Res (Phila); 2017 Jun; 10(6):337-344. PubMed ID: 28465362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
    Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
    Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Landscape of natural killer cell activity in head and neck squamous cell carcinoma.
    Charap AJ; Enokida T; Brody R; Sfakianos J; Miles B; Bhardwaj N; Horowitz A
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural killer cells have a synergistic anti-tumor effect in combination with chemoradiotherapy against head and neck cancer.
    Jung EK; Chu TH; Vo MC; Nguyen HPQ; Lee DH; Lee JK; Lim SC; Jung SH; Yoon TM; Yoon MS; Cho D; Lee JJ; Cho HH
    Cytotherapy; 2022 Sep; 24(9):905-915. PubMed ID: 35778350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of CD47 with natural killer cell-mediated cytotoxicity of head-and-neck squamous cell carcinoma lines.
    Kim MJ; Lee JC; Lee JJ; Kim S; Lee SG; Park SW; Sung MW; Heo DS
    Tumour Biol; 2008; 29(1):28-34. PubMed ID: 18497546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the Impact of Targeting CEACAM1 in Head and Neck Squamous Cell Carcinoma.
    Tam K; Schoppy DW; Shin JH; Tay JK; Moreno-Nieves U; Mundy DC; Sunwoo JB
    Otolaryngol Head Neck Surg; 2018 Jul; 159(1):76-84. PubMed ID: 29436278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
    Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of antitumor potency of extracellular vesicles derived from natural killer cells by IL-15 priming.
    Zhu L; Kalimuthu S; Oh JM; Gangadaran P; Baek SH; Jeong SY; Lee SW; Lee J; Ahn BC
    Biomaterials; 2019 Jan; 190-191():38-50. PubMed ID: 30391801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IFNalpha2b stimulated release of IFNgamma differentially regulates T cell and NK cell mediated tumor cell cytotoxicity.
    Bose A; Baral R
    Immunol Lett; 2007 Jan; 108(1):68-77. PubMed ID: 17112599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NZ28-induced inhibition of HSF1, SP1 and NF-κB triggers the loss of the natural killer cell-activating ligands MICA/B on human tumor cells.
    Schilling D; Kühnel A; Tetzlaff F; Konrad S; Multhoff G
    Cancer Immunol Immunother; 2015 May; 64(5):599-608. PubMed ID: 25854583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Purinergic targeting enhances immunotherapy of CD73
    Wang J; Lupo KB; Chambers AM; Matosevic S
    J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel inhibitor of proteasome deubiquitinating activity renders tumor cells sensitive to TRAIL-mediated apoptosis by natural killer cells and T cells.
    Sarhan D; Wennerberg E; D'Arcy P; Gurajada D; Linder S; Lundqvist A
    Cancer Immunol Immunother; 2013 Aug; 62(8):1359-68. PubMed ID: 23689729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TRAIL-mediated killing of acute lymphoblastic leukemia by plasmacytoid dendritic cell-activated natural killer cells.
    Lelaidier M; Dìaz-Rodriguez Y; Cordeau M; Cordeiro P; Haddad E; Herblot S; Duval M
    Oncotarget; 2015 Oct; 6(30):29440-55. PubMed ID: 26320191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.